Article: Mastocytic Enterocolitis: Increased Mucosal Mast Cells in Chronic Intractable Diarrhea

Article: FDA Approves Medtronic Synergy(R) Therapy for Chronic ...
PR Newswire;  November 22, 1999 ;     700+ words ... ... dual channel therapy designed to aid in the management of chronic intractable pain of the trunk or limbs, has been approved by the ... Drug Administration (FDA). Successfully controlling chronic intractable pain, such as low-back pain, has been challenging ...

Article: Cognetix Announces Mechanism of Action for Its Lead Compound -- ...
Business Wire;  September 27, 2005 ;     700+ words ... ... compound in clinical development for the treatment of chronic intractable pain. Following extensive studies, Cognetix scientists ... will be a safe and effective drug for the treatment of chronic intractable pain. Phase II clinical trials are forecast to commence ...

Article: FDA Grants Orphan Drug Designation to Cognetix' Investigational ...
Business Wire;  August 30, 2005 ;     700+ words ... ... biotechnology company focused on the development of drugs for chronic intractable pain, today announced that the U.S. Food and Drug ... completed a Phase 1b clinical trial for the treatment of chronic, intractable pain at Brigham and Womens Hospital in Boston. About ...

Article: Orphan drug status granted.(Cognetix Inc. developed CGX- 1160 to ...
Chain Drug Review;  September 26, 2005 ;     644 words ...The FDA has granted an orphan drug designation to CGX- 1160 for the treatment of chronic intractable pain. The compound was developed by Cognetix Inc., a biotechnology company.

Article: CELGENE'S THALIDOMIDE IN PHASE II CLINICAL TRIAL FOR TREATMENT OF ...
PR Newswire;  April 15, 1996 ;     700+ words ... ... CELG) said it initiated a Phase II clinical trial of its thalidomide drug Synovir(TM) for the treatment of chronic intractable diarrhea in HIV positive patients. The study has begun enrolling in London with further sites expected to open ...

Article: Ondansetron treatment in a child presenting with chronic ...
Pain Research & Management : The Journal of the Canadian Pain Society;  January 1, 2006 ;     700+ words ...The case of a seven-year-old hoy with chronic pruritus secondary to a giant congenital melanocytic nevus is presented. The pruritus did not respond to conventional antipruritic drug treatment, hut responded to ondansetron, a selective antagonist of 5-hydroxytryptamine type 3 receptors. Key Words:

Article: Surgical outcome of cortical dysplasias presenting with ...
Neurology India;  April 1, 2008 ;     700+ words ...Cortical dysplasia (CD) is an uncommon pathology causing intractable epilepsy. Over the recent years, more cases are being recognized with improvement in diagnostics and imaging. Since the inception of the epilepsy surgery program in 1995, we have operated upon more than 400 cases of intractable